Clinical Trials Logo

Coronary Aneurysm clinical trials

View clinical trials related to Coronary Aneurysm.

Filter by:

NCT ID: NCT06220682 Completed - Clinical trials for Coronary Artery Ectasia

Endothelial NO Synthase Polymorphic Gene in Coronary Artery Dilation Disease

Start date: December 1, 2020
Phase:
Study type: Observational [Patient Registry]

Introduction: The coronary artery dilatations disease (Coronary artery aneurysm/coronary artery ectasia) characterized by inappropriate coronary artery dilations. (c.894G>T) is a gene polymorphism that may decreases eNOS enzyme activity which increases the risk for coronary heart disease by affecting released (NO) molecules. One of the most researched variations in eNOS gene is c.894G>T polymorphism, which changes amino acid sequence at position 298 from Glu (GAG) to Asp (GAT), nevertheless, its role in Coronary dilatations disease still uncertain. Aim of study: To study correlation between the c.894G>T gene polymorphism and angiographically dilated coronary artery (CAA/CAE), as well as to determine whether there is any association between this polymorphism and atherosclerotic CAD. Methodology: A comparative study on 100 patients with acute coronary syndrome who underwent coronary angiography from December 2020 to June 2022. According to standard angiographic views and expert opinions, patients were divided as, 25 patients normal, 25 patients had only atherosclerotic coronary artery disease, 25 patients had dilated coronaries (CAA/CAE) without atherosclerosis and 25 patients had dilated coronaries with atherosclerotic coronary artery disease. The specific genetic PCR laboratory test were performed for eNOS SNPs (single nucleotide polymorphism) namely, 894G > T (Glu298Asp; rs 1799983), using Real-Time PCR.

NCT ID: NCT06057987 Recruiting - Clinical trials for Coronary Artery Ectasia

Coronary Artery Ectasia Database - Poland

CARED-POL
Start date: July 14, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to comprehensively investigate the current prevalence, morphological characteristics, risk factors for the development, complications as well as long-term prognosis of coronary artery aneurysm and ectasia (CAAE) in the Polish population. Data obtained from the CARED-POL Registry will enable the selection of morphological risk factors for the unfavorable course of CAAE, including the progression and development of giant aneurysms, aneurysm clotting with vessel occlusion, and thromboembolic complications. Comparing the safety and effectiveness of available CAAE treatment methods in individual patient subgroups will allow individualization of treatment, including anticoagulant therapy.

NCT ID: NCT06001957 Completed - Coronary Aneurysm Clinical Trials

Whole Exome Sequencing in Coronary Artery Ectasia

Start date: March 23, 2022
Phase:
Study type: Observational

The goal of this observational study is to assess the role of the whole exome sequencing (WES) application in patients with giant coronary artery ectasia (CAE) with a high-risk of genetic background. The main question it aims to answer are: - the assessment of role of WES in CAE - the detection of novel pathogenic mutations associated with CAE development

NCT ID: NCT05718531 Not yet recruiting - Clinical trials for Coronary Artery Ectasia

Coronary Artery Ectasia, Efficacy of Various Anti Thrombotic Regimens.

Start date: February 1, 2023
Phase: Phase 3
Study type: Interventional

1. To evaluate short and intermediate clinical outcome of different anti-thrombotic regimens on major adverse cardiac events (MACE) and quality of life in coronary artery ectasia patients. 2. To evaluate role of P-selectin as a marker of cardiovascular risk in coronary artery ectasia.

NCT ID: NCT05713201 Recruiting - Coronary Disease Clinical Trials

Outcomes After PCI of the Aneurysmatic Right Coronary Artery

RIGHT-MARE
Start date: November 1, 2022
Phase:
Study type: Observational

This study aims to evaluate procedural and clinical outcomes of acute coronay syndrome (ACS) patients with aneurysmatic culprit right coronary artery (RCA).

NCT ID: NCT05692115 Not yet recruiting - Clinical trials for Coronary Artery Ectasia

Ischemia and Inflammatory Markers Among Patients With Coronary Artery Ectasia

Start date: January 2023
Phase:
Study type: Observational

study the ischemic burden in patients with CAE, and its relation to inflammatory markers. - To assess the ischemic response during exercise ECG among patients with different variants of CAE. - To assess inflammatory biomarkers among patient with different variants of CAE - To assess the relation between the ischemic response and inflammatory markers.

NCT ID: NCT05643651 Not yet recruiting - Kawasaki Disease Clinical Trials

Rivaroxaban for Children With Giant Coronary Artery Aneurysms After Kawasaki Disease

Start date: March 1, 2024
Phase: Phase 4
Study type: Interventional

Based on population pharmacokinetic model-based simulation, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after acute Kawasaki disease was proposed. This exploratory trial aims to evaluate the feasibility, safety and effectiveness of rivaroxaban compared to warfarin for thromboprophylaxis in children with giant coronary artery aneurysms after Kawasaki disease

NCT ID: NCT05410678 Completed - Clinical trials for Coronary Artery Ectasia

Safety And Efficacy Results of Percutaneous Renal Stent Implantation in Ectatic and Aneurysmatic Coronary Arteries

Start date: June 1, 2015
Phase: Phase 4
Study type: Interventional

The aim of this study was to evaluate the efficacy and safety of renal stents implanted in ectatic/aneurysmatic coronary arteries.

NCT ID: NCT05233124 Recruiting - Clinical trials for Acute Coronary Syndrome

Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia

OVER-TIME
Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

The optimal anti-thrombotic therapy to prevent recurrent ischemic events in patients with acute coronary syndrome and coronary artery ectasia (CAE) remains unclear. OVER-TIME is an investigator initiated, exploratory, open label, single center, randomized clinical trial comparing dual antiplatelet therapy (acetyl-salicylic acid plus a P2Y12 inhibitor) with the combination of an antiplatelet monotherapy (a P2Y12 inhibitor) plus a low dose anticoagulant (rivaroxaban, 15mg oral dose) for the prevention of recurrent ischemic events among patients with CAE. The investigators aim to enroll 60 patients with CAE and acute coronary syndromes. After recruitment, patients are randomized to (a) standard of care (dual antiplatelet regimen) or (b) the combination of antiplatelet monotherapy and low dose anticoagulant. Patients will be followed for at least 12 months. The OVER-TIME study aims to assess the efficacy of the regimen in prevention of major cardiovascular events and its security in bleeding events in acute coronary syndromes among patients with CAE. OVER-TIME is the first randomized controlled trial to assess different antithrombotic strategies in patients with CAE and acute coronary syndrome, and its results will offer preliminary data for the prevention of major cardiovascular events and bleeding events in this group of patients.

NCT ID: NCT05213429 Not yet recruiting - Clinical trials for Coronary Artery Ectasia

Jordanian Coronary Artery Ectasia Registry

JoCAER
Start date: June 1, 2022
Phase:
Study type: Observational

This research project is the first in Jordan providing detailed registration of coronary ectasia cases provided by their primary healthcare providers. The investigators responsible for conducting this research are physicians and their teams who deal with patients with coronary ectasia in their clinics including the public and private medical sectors in Jordan's' medical community. Standards in Jordan complies with the recognized guidelines directed medical practices internationally.